Livingstone Health appointed by MOH to procure, deliver Sinovac vaccines to Singapore

Catalist-listed Livingstone Health has posted a net loss of $16.7 million in the 15 months (or FY2021) ended March. The group, after completing its reverse takeover (RTO) on Feb 5, changed its financial year end to March, from the FY2019 ended Dec 31, 2019 previously.

 

Loss per share for the FY2021 stood at 5.28 cents on a fully diluted basis for the group&rsquo s continuing operations.

 

Excluding RTO-related exceptional items, which stood at $18.9, Livingstone would have recorded net profit after tax of $3.5 million, 745% higher than net profit after tax of $420,000 in the FY2019.

 

Earnings per share (EPS) would have stood at 1.15 cents for the FY2021, excluding the exceptional items.

 

Net asset value (NAV) per share would have stood at 6.91 cents as at March 31.

 

Livingstone Health Holdings, which was formerly known as Citicode, was incorporated in Singapore on April 8, 2004. It is a Singapore-based multidisciplinary specialist healthcare group specialising in the fields of aesthetics and wellness, anesthesiology and pain management, family medicine, internal medicine and orthopaedic surgery.

 

Revenue for the FY2021 stood 294.2% higher y-o-y at $24.3 million mainly due to higher contributions from the group&rsquo s 51%-owned primarily healthcare arm, Phoenix Medical Group, which was acquired in December 2019. It was also boosted by higher revenue from the anesthesiology and pain management revenue contributed by the newly-added orthopaedic surgery segment as well as revenues contributed by the new family medicine and new internal medicine segments.

 

Other income rose to $1.0 million mainly due to government grants and other reliefs, as well as rental income.

 

Profit before exceptional items rose 740% y-o-y to $4.1 million.